Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.

Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group.

Leuk Res. 2018 Nov 13;76:1-10. doi: 10.1016/j.leukres.2018.11.006. [Epub ahead of print]

PMID:
30468991
Free Article
2.

Dual cholinergic signals regulate daily migration of hematopoietic stem cells and leukocytes.

García-García A, Korn C, García-Fernández M, Domingues O, Villadiego J, Martín-Perez D, Isern J, Bejarano-García JA, Zimmer J, Pérez-Simón JA, Toledo-Aral JJ, Michel T, Airaksinen MS, Méndez-Ferrer S.

Blood. 2018 Oct 25. pii: blood-2018-08-867648. doi: 10.1182/blood-2018-08-867648. [Epub ahead of print]

PMID:
30361261
3.

RIPK1 is a critical modulator of both tonic and TLR-responsive inflammatory and cell death pathways in human macrophage differentiation.

Buchrieser J, Oliva-Martin MJ, Moore MD, Long JCD, Cowley SA, Perez-Simón JA, James W, Venero JL.

Cell Death Dis. 2018 Sep 24;9(10):973. doi: 10.1038/s41419-018-1053-4.

4.

Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".

García-Guerrero E, Sánchez-Abarca LI, Domingo E, Ramos TL, Bejarano-García JA, Gonzalez-Campos JA, Caballero-Velázquez T, Pérez-Simón JA.

Front Immunol. 2018 Sep 3;9:1971. doi: 10.3389/fimmu.2018.01971. eCollection 2018.

5.

IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML.

Lopez-Millan B, Diaz de la Guardia R, Roca-Ho H, Anguita E, Islam ABMMK, Romero-Moya D, Prieto C, Gutierrez-Agüera F, Bejarano-Garcia JA, Perez-Simon JA, Costales P, Rovira M, Marín P, Menendez S, Iglesias M, Fuster JL, Urbano-Ispizua A, Anjos-Afonso F, Bueno C, Menendez P.

Oncoimmunology. 2018 Jul 26;7(9):e1477460. doi: 10.1080/2162402X.2018.1477460. eCollection 2018.

6.

Noninvasive prenatal diagnosis by cell-free DNA screening for fetomaternal HPA-1a platelet incompatibility.

Ferro M, Macher HC, Fornés G, Martín-Sánchez J, Jimenez-Arriscado P, Molinero P, Pérez-Simón JA, Guerrero JM, Rubio A.

Transfusion. 2018 Oct;58(10):2272-2279. doi: 10.1111/trf.14837. Epub 2018 Sep 17.

PMID:
30222855
7.

Vitamin D: Effect on Haematopoiesis and Immune System and Clinical Applications.

Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA.

Int J Mol Sci. 2018 Sep 8;19(9). pii: E2663. doi: 10.3390/ijms19092663. Review.

8.

Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.

Rodríguez-Arbolí E, Márquez-Malaver FJ, Rodríguez-Torres N, Caballero-Velázquez T, Escamilla-Gómez V, Calderón-Cabrera C, Falantes-González JF, Solé-Rodríguez M, García-Ramírez P, Moya-Arnao M, Carreras E, Espigado-Tocino I, Pérez-Simón JA.

Biol Blood Marrow Transplant. 2018 Aug 25. pii: S1083-8791(18)30490-7. doi: 10.1016/j.bbmt.2018.08.019. [Epub ahead of print]

PMID:
30153492
9.

Therapeutic implications of NK cell regulation of allogeneic CD8 T cell-mediated immune responses stimulated through the direct pathway of antigen presentation in transplantation.

Rodriguez-Barbosa JI, Ferreras MC, Buhler L, Jones ND, Schneider P, Perez-Simon JA, Del Rio ML.

MAbs. 2018 Oct;10(7):1030-1044. doi: 10.1080/19420862.2018.1502127. Epub 2018 Sep 5.

10.

PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation.

Santos N, Rodríguez-Romanos R, de la Cámara R, Brunet S, Nieto JB, Buño I, Martínez C, Jiménez-Velasco A, Vallejo C, González M, Solano C, Ferrá C, Sampol A, Pérez-Simón JA, López-Jiménez J, Díez JL, Gallardo D; GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH).

Ann Hematol. 2018 Nov;97(11):2217-2224. doi: 10.1007/s00277-018-3438-y. Epub 2018 Jul 17.

PMID:
30019128
11.

Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome.

Falantes JF, Márquez-Malaver FJ, Calderón-Cabrera C, Pedrote B, Martino ML, González J, Espigado I, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):469-474.e1. doi: 10.1016/j.clml.2018.05.004. Epub 2018 May 10.

PMID:
29807802
12.

Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.

Molinos-Quintana A, Trujillo-Hacha P, Piruat JI, Bejarano-García JA, García-Guerrero E, Pérez-Simón JA, Muñoz M.

Invest New Drugs. 2018 May 2. doi: 10.1007/s10637-018-0607-8. [Epub ahead of print]

PMID:
29721755
13.

Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells.

García-Calderón CB, Bejarano-García JA, Tinoco-Gago I, Castro MJ, Moreno-Gordillo P, Piruat JI, Caballero-Velázquez T, Pérez-Simón JA, Rosado IV.

Cell Death Differ. 2018 Nov;25(11):1967-1979. doi: 10.1038/s41418-018-0089-4. Epub 2018 Mar 6.

PMID:
29511342
14.

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups.

Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x.

PMID:
29473097
15.

Clinical association of anti-glutathione S-transferase T1 antibodies and de novo immune hepatitis after hematopoietic cell transplantation.

Aguado-Dominguez E, Sousa JM, Perez-Simon JA, Aguilera I.

Dig Liver Dis. 2018 Apr;50(4):418-419. doi: 10.1016/j.dld.2017.12.033. Epub 2018 Jan 31. No abstract available.

PMID:
29409781
16.

A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups.

Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Erratum in: Ann Hematol. 2018 Feb 23;:.

PMID:
29392425
17.

De novo recipient-specific Glutathione S-transferase T1 antibody development after HLA-identical hematopoietic cell transplantation.

Martínez-Bravo MJ, Sánchez B, Acevedo MJ, Pérez-Simón JA, Núñez-Roldán A, Aguilera I.

Transpl Immunol. 2018 Feb;46:36-41. doi: 10.1016/j.trim.2017.12.002. Epub 2017 Dec 13.

PMID:
29246878
18.

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.

Sarmiento Maldonado M, Ramírez Villanueva P, Bertín Cortes-Monroy P, Jara Arias V, Soto Donoso K, Uribe Gonzalez P, Ocqueteau Tachini M, Perez-Simón JA.

Exp Hematol Oncol. 2017 Dec 2;6:32. doi: 10.1186/s40164-017-0092-3. eCollection 2017.

19.

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.

Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Cebrecos C, Falantes J, Vázquez-López L, Montero MI, Rosso-Fernández C, de la Luz Martino M, Parody R, González-Campos J, Garzón-López S, Calderón-Cabrera C, Barba P, Rodríguez N, Rovira M, Montero-Mateos E, Carratalá J, Pérez-Simón JA, Cisneros JM.

Lancet Haematol. 2017 Dec;4(12):e573-e583. doi: 10.1016/S2352-3026(17)30211-9. Epub 2017 Nov 15.

PMID:
29153975
20.

KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.

Prats-Martín C, Jiménez-Guerrero P, Morales-Camacho RM, Caballero-Velázquez T, Vargas MT, Pérez O, Montero I, Falantes J, Burillo-Sanz S, Carrillo E, Borrero JJ, Bernal R, Pérez-Simón JA.

Ann Hematol. 2018 Mar;97(3):533-535. doi: 10.1007/s00277-017-3187-3. Epub 2017 Nov 18. No abstract available.

PMID:
29151134
21.

Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches.

Gallardo D, Bosch-Vizcaya A, Rodríguez-Romanos R, Santos N, Buño I, de la Cámara R, Brunet S, Jiménez-Velasco A, González M, Nieto JB, Martínez-Laperche C, Vallejo C, Ferrá C, Sampol A, López-Jiménez J, Pérez-Simón JA, Martínez C, Díez JL; GvHD/Immunotherapy Committee of the Spanish Hematopoietic Transplant Group.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2042-2047. doi: 10.1016/j.bbmt.2017.08.003. Epub 2017 Aug 4.

22.

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M.

Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5. No abstract available.

23.

The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.

Falantes JF, Márquez-Malaver FJ, Knight T, Calderón-Cabrera C, Martino ML, González J, Montero I, Espigado I, Pérez-Simón JA.

Leuk Lymphoma. 2017 Aug;58(8):1893-1902. doi: 10.1080/10428194.2016.1267350. Epub 2016 Dec 12.

PMID:
27951729
24.

Sensitivity of hematopoietic stem cells to mitochondrial dysfunction by SdhD gene deletion.

Bejarano-García JA, Millán-Uclés Á, Rosado IV, Sánchez-Abarca LI, Caballero-Velázquez T, Durán-Galván MJ, Pérez-Simón JA, Piruat JI.

Cell Death Dis. 2016 Dec 8;7(12):e2516. doi: 10.1038/cddis.2016.411.

25.

Intravascular lymphoma: look through the small vessels.

Prats-Martín C, Franco-Macías E, Morales-Camacho RM, Pérez O, Vargas MT, de la Cruz Vicente F, Borrero JJ, Bernal R, Pérez-Simón JA.

Ann Hematol. 2017 Mar;96(3):517-519. doi: 10.1007/s00277-016-2874-9. Epub 2016 Nov 12. No abstract available.

PMID:
27838775
26.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA.

Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.

PMID:
27819684
27.

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA.

Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. No abstract available.

PMID:
27295268
28.

Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.

Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético).

Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. Epub 2016 Jun 29.

29.

Candida parapsilosis misleading the automated absolute and differential white blood cell count.

Verdesoto-Cozzarelli S, Prats-Martín C, Morales-Camacho RM, Pérez de Soto C, Ruiz M, de Blas JM, Bernal R, Pérez-Simón JA.

Ann Hematol. 2017 Jan;96(1):169-170. doi: 10.1007/s00277-016-2851-3. Epub 2016 Oct 27. No abstract available.

PMID:
27785564
30.

Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo.

Barbado MV, Medrano M, Caballero-Velázquez T, Álvarez-Laderas I, Sánchez-Abarca LI, García-Guerrero E, Martín-Sánchez J, Rosado IV, Piruat JI, Gonzalez-Naranjo P, Campillo NE, Páez JA, Pérez-Simón JA.

Int J Cancer. 2017 Feb 1;140(3):674-685. doi: 10.1002/ijc.30483. Epub 2016 Nov 10.

31.

Caspase-8 inhibition represses initial human monocyte activation in septic shock model.

Oliva-Martin MJ, Sanchez-Abarca LI, Rodhe J, Carrillo-Jimenez A, Vlachos P, Herrera AJ, Garcia-Quintanilla A, Caballero-Velazquez T, Perez-Simon JA, Joseph B, Venero JL.

Oncotarget. 2016 Jun 21;7(25):37456-37470. doi: 10.18632/oncotarget.9648.

32.

Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.

Del Rio ML, Bravo Moral AM, Fernandez-Renedo C, Buhler L, Perez-Simon JA, Chaloin O, Alvarez Nogal R, Fernandez-Caso M, Rodriguez-Barbosa JI.

Transl Res. 2017 Mar;181:83-95.e3. doi: 10.1016/j.trsl.2016.09.004. Epub 2016 Sep 15.

PMID:
27702550
33.

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-Simon JA, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N.

Leuk Lymphoma. 2017 Apr;58(4):797-808. doi: 10.1080/10428194.2016.1228926. Epub 2016 Sep 21.

34.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Lopez-Corral L, Solano C, Armand P, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1808-1815. doi: 10.1016/j.bbmt.2016.07.006. Epub 2016 Jul 25.

35.

The Dynamics of the Human Leukocyte Antigen Head Domain Modulates Its Recognition by the T-Cell Receptor.

García-Guerrero E, Pérez-Simón JA, Sánchez-Abarca LI, Díaz-Moreno I, De la Rosa MA, Díaz-Quintana A.

PLoS One. 2016 Apr 28;11(4):e0154219. doi: 10.1371/journal.pone.0154219. eCollection 2016.

36.

RUNX1 amplification in AML with myelodysplasia-related changes and ring 21 chromosomes.

Burillo-Sanz S, Vargas MT, Morales-Camacho RM, Caballero-Velázquez T, Sánchez J, García-Lozano JR, Pérez de Soto I, Prats-Martín C, Bernal R, Pérez-Simón JA.

Hematol Oncol. 2017 Dec;35(4):894-899. doi: 10.1002/hon.2287. Epub 2016 Mar 7.

PMID:
26947932
37.

Pre-transplant diastolic but not systolic dysfunction has a negative prognostic impact after allogeneic stem cell transplantation.

Sarmiento M, Parody R, Márquez-Malaver F, Espigado I, Falantes J, Caballero T, Calderón C, Carmona M, López Haldon J, Pérez-Simón JA.

Bone Marrow Transplant. 2016 Jun;51(6):863-5. doi: 10.1038/bmt.2016.8. Epub 2016 Feb 8. No abstract available.

PMID:
26855153
38.

Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells.

del Rio ML, Fernandez-Renedo C, Chaloin O, Scheu S, Pfeffer K, Shintani Y, Perez-Simon JA, Schneider P, Rodriguez-Barbosa JI.

MAbs. 2016;8(3):478-90. doi: 10.1080/19420862.2015.1132130. Epub 2016 Jan 11. Erratum in: MAbs. 2016 Nov/Dec;8(8):1620.

39.

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, de la Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Bladé J, Perez-Simon JA, San Miguel JF; Spanish Myeloma Group / Program Study and Treatment of Hematological Malignancies cooperative study groups.

Blood. 2016 Mar 3;127(9):1151-62. doi: 10.1182/blood-2015-10-662320. Epub 2015 Dec 14.

40.

Strong periodic acid-schiff reaction in hypervacuolated blastic plasmacytoid dendritic cell neoplasm.

Prats-Martín C, Morales-Camacho RM, Blum-Domínguez MA, Cabrera-Pérez R, Bernal R, Caballero-Velázquez T, Pérez-Simón JA.

Diagn Cytopathol. 2016 Jan;44(1):39-40. doi: 10.1002/dc.23372. Epub 2015 Oct 15. No abstract available.

PMID:
26467980
41.

NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.

Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, Vargas MT, García-Lozano JR, Falantes JF, Prats-Martín C, Bernal R, Pérez-Simón JA.

Int J Lab Hematol. 2016 Feb;38(1):64-71. doi: 10.1111/ijlh.12435. Epub 2015 Sep 29.

PMID:
26418229
42.

PTPN13 and β-Catenin Regulate the Quiescence of Hematopoietic Stem Cells and Their Interaction with the Bone Marrow Niche.

López-Ruano G, Prieto-Bermejo R, Ramos TL, San-Segundo L, Sánchez-Abarca LI, Sánchez-Guijo F, Pérez-Simón JA, Sánchez-Yagüe J, Llanillo M, Hernández-Hernández Á.

Stem Cell Reports. 2015 Oct 13;5(4):516-31. doi: 10.1016/j.stemcr.2015.08.003. Epub 2015 Sep 3.

43.

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.

Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group.

Haematologica. 2015 Oct;100(10):1294-300. doi: 10.3324/haematol.2015.129577. Epub 2015 Jul 9.

44.

Methionine synthase reductase deficiency (CblE): A report of two patients and a novel mutation.

Ruiz-Mercado M, Vargas MT, de Soto IP, Pecellín CD, Sánchez MC, Delgado MA, Ruiz RB, Pérez-Simón JA, Díaz-Aguado AH.

Hematology. 2016 Apr;21(3):193-7. doi: 10.1179/1607845415Y.0000000017. Epub 2015 May 15.

PMID:
25978498
45.

Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.

Molinos-Quintana A, Aquino V, Montero I, Pérez-de Soto C, García-Lozano R, Pérez-Simón JA, Pérez-Hurtado JM.

Acta Haematol. 2015;134(2):71-5. doi: 10.1159/000371831. Epub 2015 Apr 18.

PMID:
25895602
46.

Evaluation of a method for murine monocyte isolation by bone marrow depletion.

Oliva-Martin MJ, Sánchez-Abarca LI, Carrillo-Jiménez A, Pérez-Simón JA, Venero JL.

Anal Biochem. 2015 Jul 1;480:42-8. doi: 10.1016/j.ab.2015.04.012. Epub 2015 Apr 16.

PMID:
25892220
47.

Human Bone Marrow Stromal Cells Differentiate Into Corneal Tissue and Prevent Ocular Graft-Versus-Host Disease in Mice.

Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, Herrero C, Velasco A, Carrancio S, Caballero-Velázquez T, Rodríguez-Barbosa JI, Parrilla M, Del Cañizo C, San Miguel J, Aijón J, Pérez-Simón JA.

Cell Transplant. 2015;24(12):2423-33. doi: 10.3727/096368915X687480. Epub 2015 Feb 18.

PMID:
25695936
48.

Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Báez A, Piruat JI, Caballero-Velázquez T, Sánchez-Abarca LI, Álvarez-Laderas I, Barbado MV, García-Guerrero E, Millán-Uclés Á, Martín-Sánchez J, Medrano M, Pérez-Simón JA.

Am J Cancer Res. 2014 Dec 15;5(1):386-95. eCollection 2015.

49.

Anti-common γ-chain antibody: one for all in GVHD.

Pérez-Simón JA.

Blood. 2015 Jan 15;125(3):424-6. doi: 10.1182/blood-2014-12-610659. No abstract available.

50.

Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.

Falantes JF, Trujillo P, Piruat JI, Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez M, González J, Martino ML, Montero I, Parody R, Espigado I, Urbano-Ispizua A, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.

PMID:
25487600

Supplemental Content

Loading ...
Support Center